Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor-Reference-Cited by-同舟云学术

Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor

Published:2011-07-28 Issue:14 Volume:54 Page:4998-5012
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Miwa Kazuhiro,Hitaka Takenori,Imada Takashi,Sasaki Satoshi,Yoshimatsu Mie,Kusaka Masami,Tanaka Akira,Nakata Daisuke,Furuya Shuichi,Endo Satoshi,Hamamura Kazumasa,Kitazaki Tomoyuki

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm200216q

Reference88 articles.

1. Gonadotropin-Releasing Hormone: One Polypeptide Regulates Secretion of Luteinizing and Follicle-Stimulating Hormones

2. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence

3. Gonadotropin-Releasing Hormone Receptors

4. Studies of Gonadotropin-Releasing Hormone (GnRH) Action Using GnRH Receptor-Expressing Pituitary Cell Lines

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An alternative and scalable synthesis for Relugolix;Tetrahedron;2024-11

2. Synthetic approaches and application of representative clinically approved fluorine-enriched anti-cancer medications;European Journal of Medicinal Chemistry;2024-10

3. Design and Efficient Synthesis of New 4-Amino-Substituted 2-(4-Bromobenzyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidines of Anticancer Interest and Their In Silico Study;Synthesis;2024-07-16

4. The role of the methoxy group in approved drugs;European Journal of Medicinal Chemistry;2024-07

5. Impact of relugolix combination therapy on functioning and quality of life in women with endometriosis-associated pain;Fertility and Sterility;2024-06